Paris and Boston, January 26, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) announces today the initiation of coverage of its stock by the financial research firm Allinvest Securities.
In a study entitled “Après la sauvegarde, le réveil de la croissance” (After the safeguard proceedings, the rebirth of growth), Allinvest Securities issues a BUY recommendation with a target price of €0.20 per share, representing a potential upside of +54% compared to the closing share price on January 23, 2026 (€0.13).
As a reminder, the stock is already covered by Euroland Corporate with a price target of €0.50.
